Compare · LMDX vs ORKA
LMDX vs ORKA
Side-by-side comparison of LumiraDx Limited (LMDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $6.53B.
- ORKA has hit the wire 12 times in the past 4 weeks while LMDX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 4 for LMDX).
- Company
- LumiraDx Limited
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- -
- $6.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 12
- Recent ratings
- 4
- 11
Latest LMDX
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form SC 13G/A filed by LumiraDx Limited (Amendment)
- SEC Form 6-K filed by LumiraDx Limited
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- LumiraDx shares are trading lower after the company announced its securities will be suspended from trading on Nasdaq at the open of business tomorrow.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
- US Stocks Mixed; Nasdaq Jumps Over 100 Points
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $706,700 worth of shares (7,000 units at $100.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Oruka Therapeutics Inc.